Millions of Australians at risk of type 2 diabetes just got a glimmer of hope. The potentially life-changing medication Wegovy (semaglutide) is set to become more accessible, thanks to a recent recommendation by the Pharmaceutical Benefits Advisory Committee (PBAC). This move could significantly impact the fight against obesity and its devastating consequences, particularly for those with existing cardiovascular disease. But here's where it gets controversial: should taxpayer dollars subsidize weight loss medications, even if they prevent costly chronic conditions down the line?
The PBAC has recommended that Wegovy be subsidized through the Pharmaceutical Benefits Scheme (PBS) for adults with established cardiovascular disease and obesity. This means individuals who have experienced a heart attack, stroke, or suffer from symptomatic peripheral arterial disease could soon access this medication at a significantly reduced cost. Diabetes Australia's Group CEO, Justine Cain, warmly welcomed the news, highlighting the government's commitment to working with manufacturer Novo Nordisk to make this a reality.
"Empowering individuals to manage their weight is crucial in preventing type 2 diabetes," Cain emphasized. "While genetics play a role, a staggering 58% of type 2 diabetes cases can be prevented or delayed. Making medications like Wegovy more affordable is a vital tool in this fight."
The PBAC's published recommendation outlines specific criteria for eligibility, ensuring the subsidy targets those most in need. This targeted approach aims to maximize the impact of the program while managing costs.
This recommendation comes on the heels of a joint submission by the Diabetes Alliance, led by Diabetes Australia, to the PBAC's November 2025 meeting. The Alliance advocated for improved access to GLP-1 RA medications like semaglutide, citing their potential to combat obesity and reduce the risk of chronic conditions like type 2 diabetes and heart disease.
"It's heartening to see our sector's voice being heard," Cain remarked. "This separate recommendation for Wegovy is a significant step forward in managing obesity and our ongoing battle against chronic diseases in Australia."
With over 1.3 million Australians living with type 2 diabetes and another 2 million at risk, the potential impact of this decision is immense.
But is subsidizing weight loss medication the best use of public funds? While the long-term benefits of preventing chronic diseases are undeniable, some argue that individual responsibility should play a larger role in managing weight. What do you think? Is this a wise investment in public health, or a step too far? Let us know your thoughts in the comments below.
The Diabetes Alliance comprises Diabetes Australia, the Australian Diabetes Educators Association, the Australian Diabetes Society, Breakthrough T1D, the Australasian Diabetes in Pregnancy Society, and the Australian and New Zealand Society for Paediatric Endocrinology and Diabetes.
